Abstract:BACKGROUND:Adjuvant chemotherapy is currently offered routinely, as standard, after radical resection for patients with rectal cancer receiving neo-adjuvant chemoradiation. However, the efficacy of adjuvant chemotherapy in patients with ypTis-2N0M0 has not been documented to the same extent, and the survival benefit remained controversial. The purpose of this work was to determine the role of chemotherapy in patients with ypTis-2N0M0 classification. MATERIALS AND METHODS:Data were obtained from the Surveillance, Epidemiology, and End Results database (n = 4,217). A propensity score model was utilized to balance baseline covariates. RESULTS:Of the 4,217 included patients, 335 with ypTis-2N0M0 did not receive adjuvant chemotherapy. There were comparable cancer-specific survivals (CSS) between those undergoing adjuvant chemotherapy or not (log-rank test = 0.136, p = .712) in the overall sample. After propensity score matching, the cancer-specific survival did not differ between the chemotherapy and observation groups (log-rank test = 0.089, p = .765). Additionally, the Cox model did not demonstrate adjuvant chemotherapy as the prognostic factor, with hazard ratio = 0.95 (95% confidence interval 0.69-1.32) for CSS. Furthermore, the 10-year cumulative CSS was 78.7% and 79.4% between the chemotherapy and observation groups, indicating no significance, and no impact of adjuvant chemotherapy on survival was observed in different subgroups stratified by T stage, histological grade, histology, lymph nodes, and tumor size. CONCLUSION:Patients with ypTis-2N0 rectal cancer did not benefit from adjuvant chemotherapy after preoperative radiology and radical surgery in this cohort study. These results provided new insight into the routine use of adjuvant chemotherapy for patients with rectal cancer with completed neo-adjuvant radiotherapy and curative surgery. IMPLICATIONS FOR PRACTICE:Inconsistent recommendations for patients with rectal cancer receiving neo-adjuvant chemoradiation are offered by clinical guidelines. Adjuvant chemotherapy had no cancer-specific survival benefit, not only in the whole cohort, but also in the propensity score-matched cohort. A Cox model also confirmed adjuvant chemotherapy was not a significant prognostic factor in ypTis-2N0 rectal cancer. No survival benefit conferred by adjuvant chemotherapy was observed, regardless of whether T stage, histological type, grade, lymph nodes and tumor size varied.

Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Meta-Analysis of Colorectal Cancer Survival Data

Predictive Value of Thymidylate Synthase Expression in Advanced Colorectal Cancer Patients Receiving Fluoropyrimidine‐based Chemotherapy: Evidence from 24 Studies

Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability

Thymidylate synthase expression in colon carcinomas with microsatellite instability

The Pemetrexed-Containing Treatments in the Non-small Cell Lung Cancer, is -/Low Thymidylate Synthase Expression Better Than +/high Thymidylate Synthase Expression? A Meta-analysis

Prognostic values of tumor-stroma ratio and tumor-infiltrating lymphocytes in stagesⅡandⅢcolorectal cancer

Could Adjuvant Chemotherapy Improve Prognosis For Cervical Cancer Patients With Elevated Pretreatment Serum Squamous-Cell Carcinoma Antigen?

HER-2 Overexpression and Survival in Colorectal Cancer: a Meta-Analysis

Correlation Research of Thymidine Synthase Expression in Circulating Tumor Cell and Clinical Characteristics of Colon Cancer.

Assessing the effectiveness of targeted agents in adjuvant therapy for patients with metastatic colorectal cancer undergoing surgical resection: a retrospective cohort study

Thymidylate Synthase Predicts for Clinical Outcome in Invasive Breast Cancer.

Role of TSP-1 As Prognostic Marker in Various Cancers: a Systematic Review and Meta-Analysis

The Relationship Between the Thymidylate Synthase Mrna Expression and Clinical Prognostic in Esophageal Squamous Cell Carcinoma Patients Treated with 5-Flurouracil-based Chemotherapy

[Prognostic Value of Thymidylate Synthase, Topoisomerase-1 and Ki-67 in Advanced Colorectal Cancer Patients on Irinotecan and Fluorouracil Treatment].

Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer

Expression of Thymidine Phosphorylase in Human Colorectal Carcinoma and Its Clinical Significance

p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy

The Prognostic Value of Survivin Expression in Patients with Colorectal Carcinoma: A Meta-Analysis

The mRNA expressions and the clinical significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal carcinoma

Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis.

[Relationships among the Expression of Thymidylate Synthase, Thymidine Phosphorylase, and Dihydropyrimidine Dehydrogenase and the Prognosis of Breast Cancer].